Announced details
Prevention of peptic ulcers associated with NSAID administration; erosive gastroesophageal reflux disease; non-erosive gastroesophageal reflux disease; gastric ulcers; adjunctive therapy for Helicobacter pylori eradication; and maintenance therapy following healing of erosive gastroesophageal reflux disease
At week 24, tegoprazan demonstrated non-inferiority to lansoprazole. At week 12, the proportion of subjects without heartburn symptoms was statistically significantly higher than in the comparator drug group.
Domestic sales in South Korea based on prescriptions dispensed outside hospitals exceeded cumulative sales of KRW 1 trillion (approximately ¥110 billion) in April 2026. The product is sold in 20 countries, and business activities including development, manufacturing and sales are conducted in 57 countries worldwide.
RaQualia Pharma discovered tegoprazan and out-licensed it to HK inno.N. Under the license agreement, RaQualia Pharma holds the right to receive a portion of the revenue that HK inno.N receives from its partner.
Head office: Osong, South Korea. Other company details: Not disclosed.
The impact on full-year consolidated results for the fiscal year ending December 2026 is currently expected to be limited. There is no change to the full-year consolidated earnings forecast. The Company believes this will contribute to improving corporate value over the medium to long term.
The company does not address Contract Value / Offering price.
HK inno.N's official announcement and website
| Item | Details |
|---|---|
| Names of Products / Services Covered | tegoprazan, K-CAB® |
| Counterparty | HK inno.N Corporation (HK inno.N) |
| Counterparty overview | Head office: Osong, South Korea. Other company details: Not disclosed. |
| Relationship with the Company | RaQualia Pharma discovered tegoprazan and out-licensed it to HK inno.N. Under the license agreement, RaQualia Pharma holds the right to receive a portion of the revenue that HK inno.N receives from its partner. |
| Launch date | Launched in South Korea in 2019 (actual) |
| Applicable area | Prevention of peptic ulcers associated with NSAID administration; erosive gastroesophageal reflux disease; non-erosive gastroesophageal reflux disease; gastric ulcers; adjunctive therapy for Helicobacter pylori eradication; and maintenance therapy following healing of erosive gastroesophageal reflux disease |
| Quantitative Effects | At week 24, tegoprazan demonstrated non-inferiority to lansoprazole. At week 12, the proportion of subjects without heartburn symptoms was statistically significantly higher than in the comparator drug group. |
| Usage history | Domestic sales in South Korea based on prescriptions dispensed outside hospitals exceeded cumulative sales of KRW 1 trillion (approximately ¥110 billion) in April 2026. The product is sold in 20 countries, and business activities including development, manufacturing and sales are conducted in 57 countries worldwide. |
| Impact on Business Performance | The impact on full-year consolidated results for the fiscal year ending December 2026 is currently expected to be limited. There is no change to the full-year consolidated earnings forecast. The Company believes this will contribute to improving corporate value over the medium to long term. |
| Source | HK inno.N's official announcement and website |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As opportunities for the use of long-term NSAID therapy have expanded, the prevention of peptic ulcers associated with NSAID administration has become an important unmet medical need.